Trial reportAmerican heart journal2011
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
Trial report in American heart journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00120289. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events
Open the trial in the graphWho cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmacological interventions for heart failure in people with chronic kidney disease.The Cochrane database of systematic reviews · 2020Pooled it
- Statins for primary prevention of venous thromboembolism.The Cochrane database of systematic reviews · 2014Pooled it
- Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes: The MRI Substudy in AIM-HIGH.JACC. Cardiovascular imaging · 2017 · on this mapTrial
- Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.The American journal of medicine · 2016Trial
- Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.Stroke · 2013 · on this mapTrial
- Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.Vascular health and risk management · 2012Trial
- Trial
- Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial.Journal of clinical lipidologyTrial
- Expression levels of miR-22, miR-30c, miR-145, and miR-519d and their possible associations with inflammatory markers among patients with coronary artery disease.ARYA atherosclerosis · 2022Article
- Machine Learning Quantitation of Cardiovascular and Cerebrovascular Disease: A Systematic Review of Clinical Applications.Diagnostics (Basel, Switzerland) · 2021Review
- Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review.American journal of preventive cardiology · 2020Review
- Effects of Eicosapentaenoic Acid on Arterial Calcification.International journal of molecular sciences · 2020Review
- Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014.Cardiology and therapy · 2020Article
- Evaluation of Lipid Profile and Residual Cardiovascular Risk in Patients Prior to Initiation of Niaspan Therapy.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2018Article
- Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.Current diabetes reports · 2017Review
- Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence.Current diabetes reports · 2015Article
- Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Current atherosclerosis reports · 2015Review
- Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study.The international journal of cardiovascular imaging · 2015 · on this mapArticle
- Clinical factors associated with high-risk carotid plaque features as assessed by magnetic resonance imaging in patients with established vascular disease (from the AIM-HIGH Study).The American journal of cardiology · 2014 · on this mapArticle
- Exercise and dietary-mediated reductions in postprandial lipemia.Journal of nutrition and metabolism · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundThe aim of this study was to test the hypothesis that patients with atherosclerotic cardiovascular (CV) disease optimally treated on a statin but with residual atherogenic dyslipidemia (low high-density lipoprotein cholesterol [HDL-C] and high triglycerides) will benefit from addition of niacin with fewer CV events compared with placebo. Statin monotherapy trials have found 25%-35% CV risk reduction relative to placebo, leaving significant residual risk. Patients with atherogenic dyslipidemia have substantially increased CV risk.
methodsParticipants were men and women with established CV disease and atherogenic dyslipidemia. Lipid entry criteria varied by gender and statin dose at screening. All participants received simvastatin (or simvastatin plus ezetimibe) at a dose sufficient to maintain low-density lipoprotein cholesterol (LDL-C) 40-80 mg/dL (1.03-2.07 mmol/L). Participants were randomized to extended-release niacin or matching placebo. The primary end point was time to occurrence of the first of the following: coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, hospitalization for acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. This event-driven trial will have 85% power to show a 25% reduction in primary event frequency after 850 patients have experienced a primary outcome event.
resultsAIM-HIGH completed enrollment in April 2010. Follow-up is expected to continue through 2012. SUMMARY: AIM-HIGH was designed to determine whether treating residual dyslipidemia with niacin further reduces cardiovascular events in patients with CV disease on a statin at target levels of low-density lipoprotein cholesterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.